APA

Kouiavskaia D. V., Berard C. A., Datena E., Hussain A., Dawson N., Klyushnenkova E. N. & Alexander R. B. (20091005). Vaccination with agonist peptide PSA: 154-163 (155L) derived from prostate specific antigen induced CD8 T-cell response to the native peptide PSA: 154-163 but failed to induce the reactivity against tumor targets expressing PSA: a phase 2 study in patients with recurrent prostate cancer. : Journal of immunotherapy (Hagerstown, Md. : 1997).

Chicago

Kouiavskaia Diana V, Berard Carla A, Datena Ellen, Hussain Arif, Dawson Nancy, Klyushnenkova Elena N and Alexander Richard B. 20091005. Vaccination with agonist peptide PSA: 154-163 (155L) derived from prostate specific antigen induced CD8 T-cell response to the native peptide PSA: 154-163 but failed to induce the reactivity against tumor targets expressing PSA: a phase 2 study in patients with recurrent prostate cancer. : Journal of immunotherapy (Hagerstown, Md. : 1997).

Harvard

Kouiavskaia D. V., Berard C. A., Datena E., Hussain A., Dawson N., Klyushnenkova E. N. and Alexander R. B. (20091005). Vaccination with agonist peptide PSA: 154-163 (155L) derived from prostate specific antigen induced CD8 T-cell response to the native peptide PSA: 154-163 but failed to induce the reactivity against tumor targets expressing PSA: a phase 2 study in patients with recurrent prostate cancer. : Journal of immunotherapy (Hagerstown, Md. : 1997).

MLA

Kouiavskaia Diana V, Berard Carla A, Datena Ellen, Hussain Arif, Dawson Nancy, Klyushnenkova Elena N and Alexander Richard B. Vaccination with agonist peptide PSA: 154-163 (155L) derived from prostate specific antigen induced CD8 T-cell response to the native peptide PSA: 154-163 but failed to induce the reactivity against tumor targets expressing PSA: a phase 2 study in patients with recurrent prostate cancer. : Journal of immunotherapy (Hagerstown, Md. : 1997). 20091005.